Ajanta Pharma Board to Consider Q2 Results and Interim Dividend on November 3

Mumbai, October 24, 2025 – Ajanta Pharma Limited (NSE: AJANTPHARM | BSE: 532331) has disclosed that a meeting will be held on Monday, November 3, 2025, to approve the unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2025, as well as a recommendation for an interim dividend for FY2025-26.

The company has also recently filed a regulatory update to confirm November 10, 2025, as the record date for shareholders to qualify for an interim dividend, if one is eventually declared. As of 2:50 PM, Ajanta Pharma Limited shares are trading at ₹2,401, down 0.56% on the NSE.

Key Details of the Board Meeting

Ajanta Pharma Limited announces that its Board Meeting will be held on November 3, 2025, to review and approve the unaudited financial results for Q2 and H1 FY26, and approve the first interim dividend for FY2025–26.

November 10, 2025, is set as the record date for determining shareholders eligible to receive the first interim dividend. This will enable Ajanta Pharma Limited to continue to offer timely financial results and consistent dividends to its shareholders.

Dividend & Record Date Details

Ajanta Pharma’s Board will consider declaring its first interim dividend for FY2025–26 in the meeting on November 3, 2025. The company has set the record date as November 10, 2025, to determine which shareholders will receive the interim dividend.

Approval of the interim dividend will take place after the Board of Directors reviews the quarterly financial performance. The company has a history of rewarding its shareholders through regular dividend distributions over the last few years.

REF:https://nsearchives.nseindia.com/corporate/AJANTPHARM_24102025095116_BMandrecorddateIntimation.pdf

https://nsearchives.nseindia.com/corporate/AJANTPHARM_08102025124559_BMIntimation03112025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations